ClinicalTrials.gg
CompletedNCT01667900Updated Mar 7, 2016Results posted

A Study of Dulaglutide in Chinese Participants

A Phase 1 interventional study of Dulaglutide and Placebo in Diabetes Mellitus, Type 2 and Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-03-07.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
39th of 54
58 · median 159
Started
2012
with 7 others
Phase 1
15 of 54
none open now
Registered
27th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 39th largest by enrollment, is one of 8 that started in 2012, is one of 15 in phase 1, and was the 27th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a study of dulaglutide in Chinese participants. The purpose of the study is to determine how the body processes dulaglutide and how dulaglutide affects the body. This study has 2 parts: Part A - single dose of dulaglutide administered to healthy participants in 2 of 3 study periods. There is a minimum 28-day washout between periods. Part A will last approximately 16 weeks. Part B - multiple doses of dulaglutide administered to participants with Type 2 diabetes mellitus (T2DM). Part B will last approximately 15 weeks.

Doses of 0.5 milligrams (mg), 0.75 mg, and 1.5 mg of dulaglutide will be evaluated in this study.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Healthy Volunteers
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Participants:

  • Native Chinese (all 4 grandparents of Chinese origin)
  • Male participants with female partners of , or partners who are pregnant or breastfeeding, agree to use a reliable method of from the time of the first dose until 3 months after the last dose of product, as determined by the investigator.
  • The method of contraception may be one of the following: condom with spermicidal agent, male participant sterilization, true abstinence (which is in line with the participant's usual lifestyle choice; withdrawal or calendar methods are not considered acceptable).
  • Female participants not of child-bearing potential (i.e. are or permanently sterilized [e.g. tubal occlusion, hysterectomy, bilateral salpingectomy]). Such participants will not be required to use contraception but must test negative for pregnancy at the time of enrollment. Postmenopausal is defined as at least 1 year post cessation of menses (without an alternative medical cause) or at least 1 year of spontaneous amenorrhea, with follicle stimulating hormone (FSH) ≥40 milli international units per milliliter (mIU/mL).
  • Female participants who have undergone sterilization by tubal ligation: agree to use a condom in conjunction with spermicidal gel, foam, cream, film or suppository from the time of screening until 3 months after the last dose of investigational product. Such participants must also test negative for pregnancy at the time of enrollment.

Participants with T2DM:

  • Have T2DM controlled with diet or exercise alone or with a single oral agent antihyperglycemic medication (OAM) (metformin, sulfonylureas, meglitinides, acarbose [or other disaccharidase inhibitors] or thiazolidinediones) for at least 3 weeks (3 months for thiazolidinediones) before admission. Note that participants receiving sulfonylureas, meglitinides or acarbose may participate only if this treatment is stopped and metformin substituted. If switched to metformin, participants should be allowed to stabilize on metformin for 3 weeks before receiving study drug.
  • If T2DM controlled with diet or exercise alone, must have a (HbA1c) value of 6.5% to 10.5% at screening and a fasting blood glucose value of 126 to 250 milligrams per deciliter (mg/dL) (approximately 7.0 to 13.9 millimoles per liter [mmol/L]) at screening.
  • If T2DM controlled with OAM(s), must have an HbA1c value of 9.0% or less at screening and a fasting blood glucose value of 110 to 200 mg/dL (approximately 6.1 to 11.1 mmol/L) at screening. If a participant's T2DM is being controlled with OAM(s) other than metformin, the participant's OAM will be stopped for at least 3 weeks before administration of study drug.

Exclusion criteria

Exclusion Criteria:

All Participants:

  • Have a history or presence of cardiovascular (myocardial infarction, cerebrovascular accident, venous thromboembolism), respiratory, hepatic, renal, hematological, neurological or endocrine (except T2DM), disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data.
  • Have evidence of significant active neuropsychiatric disease.
  • Have poorly controlled hypertension (systolic >160 millimeters of mercury [mmHg] and/or diastolic >100 mmHg) and/or evidence of labile blood pressure including symptomatic postural hypotension.
  • Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis) or gastrointestinal disorder, for example relevant esophageal reflux or gall bladder disease, or any gastrointestinal disease which impacts gastric empty (for example, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase (DPP)-4 inhibitors. Participants with dyslipidemia, and participants who had cholecystolithiasis (removal of gall stones) and/or cholecystectomy (removal of gall bladder) in the past, with no further sequelae, may be included in the study at the discretion of the screening physician.
  • Have personal or family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC.

Participants with T2DM

  • Have experienced outpatient use of insulin for control of diabetes within the past 6 months.
  • Have peripheral vascular occlusive disease in the opinion of the investigator.
  • Have known severe exudative diabetic retinopathy in the opinion of the investigator.
  • Have known significant autonomic neuropathy as evidenced by urinary retention, diabetic diarrhea, or gastroparesis.
  • Have experienced a ketoacidotic episode (pH less than 7.3) requiring hospitalization in the last 6 months.
  • Regular use of drugs that affect the glycodynamics and that directly reduce gastrointestinal motility (eg, anticholinergics, antispasmodics, 5HT3 antagonists, dopamine antagonists, and opiates) and of systemic by oral, intravenous, or intramuscular route, or potent, inhaled, or intranasal steroids known to have a high rate of systemic absorption.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    0.5 mg Dulaglutide (Part A-Healthy)

    0.5 milligrams (mg) dulaglutide administered once subcutaneously (SQ) to healthy participants in 1 of 3 treatment periods

    Drug: Dulaglutide · Drug: Placebo

  • Experimental
    0.75 mg Dulaglutide (Part A-Healthy)

    0.75 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods

    Drug: Dulaglutide · Drug: Placebo

  • Experimental
    1.5 mg Dulaglutide (Part A-Healthy)

    1.5 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods

    Drug: Dulaglutide · Drug: Placebo

  • Placebo comparator
    Placebo (Part A-Healthy)

    Placebo administered once SQ to healthy participants in 1 of 3 treatment periods

    Drug: Placebo

  • Experimental
    0.5 mg Dulaglutide (Part B-T2DM)

    0.5 mg dulaglutide administered to participants with Type 2 diabetes mellitus (T2DM) once weekly SQ for 4 weeks

    Drug: Dulaglutide · Drug: Placebo

  • Experimental
    0.75 mg Dulaglutide (Part B-T2DM)

    0.75 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks

    Drug: Dulaglutide · Drug: Placebo

  • Experimental
    1.5 mg Dulaglutide (Part B-T2DM)

    1.5 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks

    Drug: Dulaglutide · Drug: Placebo

  • Placebo comparator
    Placebo (Part B-T2DM)

    Placebo administered to participants with T2DM once weekly SQ for 4 weeks

    Drug: Placebo

Interventions

  • Also known as: LY2189265

  • DrugPlacebo

    Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Maximum Concentration (Cmax) of Dulaglutide

    Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.

    Time frame: Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose

  2. Pharmacokinetics: Time of Maximum Observed Concentration (Tmax) of Dulaglutide

    Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.

    Time frame: Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose

  3. Pharmacokinetics: Area Under the Concentration-time Curve From Time Zero to 336 Hours Postdose (AUC[0-336]) of Dulaglutide

    Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.

    Time frame: Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose

  4. Pharmacokinetics: Half-life of Dulaglutide

    Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.

    Time frame: Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose

Secondary outcomes

  1. Part B - Pharmacodynamics: Area Under the Plasma Glucose Time Curve From Time Zero to 4 Hours Postmeal (gAUC[0-4])

    Pharmacodynamic parameters were assessed at baseline and on Days 3, 24, and 29 in Part B.

    Time frame: Baseline and Days 3, 24, and 29

07

Results

Posted Mar 7, 2016

Participant flow

Part A, Period 1
Participant flow — Part A, Period 1
MilestoneFirst 0.5 mg, Then Placebo, Then 1.5 mg (Part A-Healthy)First 0.75 mg, Then 0.5 mg, Then Placebo (Part A-Healthy)First 0.75 mg, Then 1.5 mg, Then Placebo (Part A-Healthy)First 0.5 mg, Then 1.5 mg, Then Placebo (Part A-Healthy)First 1.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy)First Placebo, Then 0.5 mg, Then 1.5 mg (Part A-Healthy)First 0.75 mg, Then Placebo, Then 1.5 mg (Part A-Healthy)First Placebo, Then 0.75 mg, Then 0.5 mg (Part A-Healthy)First Placebo, Then 0.75 mg, Then 1.5 mg (Part A-Healthy)First 0.5 mg, Then 0.75 mg, Then Placebo (Part A-Helathy)First 1.5 mg, Then 0.75 mg, Then Placebo (Part A-Healthy)First 0.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy)First 0.75 mg, Then Placebo, Then 0.5 mg (Part A-Healthy)First Placebo, Then 1.5 mg, Then 0.75 mg (Part A-Healthy)First 1.5 mg, Then 0.5 mg, Then Placebo (Part A-Healthy)First Placebo, Then 1.5 mg, Then 0.5 mg (Part A-Healthy)0.5 mg Dulaglutide (Part B-T2DM)0.75 mg Dulaglutide (Part B-T2DM)1.5 mg Dulaglutide (Part B-T2DM)Placebo (Part B-T2DM)
Started11111111111111110000
Completed11111111111111110000
Not completed00000000000000000000
Part A, Washout 1
Participant flow — Part A, Washout 1
MilestoneFirst 0.5 mg, Then Placebo, Then 1.5 mg (Part A-Healthy)First 0.75 mg, Then 0.5 mg, Then Placebo (Part A-Healthy)First 0.75 mg, Then 1.5 mg, Then Placebo (Part A-Healthy)First 0.5 mg, Then 1.5 mg, Then Placebo (Part A-Healthy)First 1.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy)First Placebo, Then 0.5 mg, Then 1.5 mg (Part A-Healthy)First 0.75 mg, Then Placebo, Then 1.5 mg (Part A-Healthy)First Placebo, Then 0.75 mg, Then 0.5 mg (Part A-Healthy)First Placebo, Then 0.75 mg, Then 1.5 mg (Part A-Healthy)First 0.5 mg, Then 0.75 mg, Then Placebo (Part A-Helathy)First 1.5 mg, Then 0.75 mg, Then Placebo (Part A-Healthy)First 0.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy)First 0.75 mg, Then Placebo, Then 0.5 mg (Part A-Healthy)First Placebo, Then 1.5 mg, Then 0.75 mg (Part A-Healthy)First 1.5 mg, Then 0.5 mg, Then Placebo (Part A-Healthy)First Placebo, Then 1.5 mg, Then 0.5 mg (Part A-Healthy)0.5 mg Dulaglutide (Part B-T2DM)0.75 mg Dulaglutide (Part B-T2DM)1.5 mg Dulaglutide (Part B-T2DM)Placebo (Part B-T2DM)
Started11111111111111110000
Completed11111111111111110000
Not completed00000000000000000000
Part A, Period 2
Participant flow — Part A, Period 2
MilestoneFirst 0.5 mg, Then Placebo, Then 1.5 mg (Part A-Healthy)First 0.75 mg, Then 0.5 mg, Then Placebo (Part A-Healthy)First 0.75 mg, Then 1.5 mg, Then Placebo (Part A-Healthy)First 0.5 mg, Then 1.5 mg, Then Placebo (Part A-Healthy)First 1.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy)First Placebo, Then 0.5 mg, Then 1.5 mg (Part A-Healthy)First 0.75 mg, Then Placebo, Then 1.5 mg (Part A-Healthy)First Placebo, Then 0.75 mg, Then 0.5 mg (Part A-Healthy)First Placebo, Then 0.75 mg, Then 1.5 mg (Part A-Healthy)First 0.5 mg, Then 0.75 mg, Then Placebo (Part A-Helathy)First 1.5 mg, Then 0.75 mg, Then Placebo (Part A-Healthy)First 0.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy)First 0.75 mg, Then Placebo, Then 0.5 mg (Part A-Healthy)First Placebo, Then 1.5 mg, Then 0.75 mg (Part A-Healthy)First 1.5 mg, Then 0.5 mg, Then Placebo (Part A-Healthy)First Placebo, Then 1.5 mg, Then 0.5 mg (Part A-Healthy)0.5 mg Dulaglutide (Part B-T2DM)0.75 mg Dulaglutide (Part B-T2DM)1.5 mg Dulaglutide (Part B-T2DM)Placebo (Part B-T2DM)
Started11111111111111110000
Completed11111111111111110000
Not completed00000000000000000000
Part A, Washout 2
Participant flow — Part A, Washout 2
MilestoneFirst 0.5 mg, Then Placebo, Then 1.5 mg (Part A-Healthy)First 0.75 mg, Then 0.5 mg, Then Placebo (Part A-Healthy)First 0.75 mg, Then 1.5 mg, Then Placebo (Part A-Healthy)First 0.5 mg, Then 1.5 mg, Then Placebo (Part A-Healthy)First 1.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy)First Placebo, Then 0.5 mg, Then 1.5 mg (Part A-Healthy)First 0.75 mg, Then Placebo, Then 1.5 mg (Part A-Healthy)First Placebo, Then 0.75 mg, Then 0.5 mg (Part A-Healthy)First Placebo, Then 0.75 mg, Then 1.5 mg (Part A-Healthy)First 0.5 mg, Then 0.75 mg, Then Placebo (Part A-Helathy)First 1.5 mg, Then 0.75 mg, Then Placebo (Part A-Healthy)First 0.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy)First 0.75 mg, Then Placebo, Then 0.5 mg (Part A-Healthy)First Placebo, Then 1.5 mg, Then 0.75 mg (Part A-Healthy)First 1.5 mg, Then 0.5 mg, Then Placebo (Part A-Healthy)First Placebo, Then 1.5 mg, Then 0.5 mg (Part A-Healthy)0.5 mg Dulaglutide (Part B-T2DM)0.75 mg Dulaglutide (Part B-T2DM)1.5 mg Dulaglutide (Part B-T2DM)Placebo (Part B-T2DM)
Started11111111111111110000
Completed11111111111111110000
Not completed00000000000000000000
Part A, Period 3
Participant flow — Part A, Period 3
MilestoneFirst 0.5 mg, Then Placebo, Then 1.5 mg (Part A-Healthy)First 0.75 mg, Then 0.5 mg, Then Placebo (Part A-Healthy)First 0.75 mg, Then 1.5 mg, Then Placebo (Part A-Healthy)First 0.5 mg, Then 1.5 mg, Then Placebo (Part A-Healthy)First 1.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy)First Placebo, Then 0.5 mg, Then 1.5 mg (Part A-Healthy)First 0.75 mg, Then Placebo, Then 1.5 mg (Part A-Healthy)First Placebo, Then 0.75 mg, Then 0.5 mg (Part A-Healthy)First Placebo, Then 0.75 mg, Then 1.5 mg (Part A-Healthy)First 0.5 mg, Then 0.75 mg, Then Placebo (Part A-Helathy)First 1.5 mg, Then 0.75 mg, Then Placebo (Part A-Healthy)First 0.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy)First 0.75 mg, Then Placebo, Then 0.5 mg (Part A-Healthy)First Placebo, Then 1.5 mg, Then 0.75 mg (Part A-Healthy)First 1.5 mg, Then 0.5 mg, Then Placebo (Part A-Healthy)First Placebo, Then 1.5 mg, Then 0.5 mg (Part A-Healthy)0.5 mg Dulaglutide (Part B-T2DM)0.75 mg Dulaglutide (Part B-T2DM)1.5 mg Dulaglutide (Part B-T2DM)Placebo (Part B-T2DM)
Started11111111111111110000
Completed11111111111111110000
Not completed00000000000000000000
Part B
Participant flow — Part B
MilestoneFirst 0.5 mg, Then Placebo, Then 1.5 mg (Part A-Healthy)First 0.75 mg, Then 0.5 mg, Then Placebo (Part A-Healthy)First 0.75 mg, Then 1.5 mg, Then Placebo (Part A-Healthy)First 0.5 mg, Then 1.5 mg, Then Placebo (Part A-Healthy)First 1.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy)First Placebo, Then 0.5 mg, Then 1.5 mg (Part A-Healthy)First 0.75 mg, Then Placebo, Then 1.5 mg (Part A-Healthy)First Placebo, Then 0.75 mg, Then 0.5 mg (Part A-Healthy)First Placebo, Then 0.75 mg, Then 1.5 mg (Part A-Healthy)First 0.5 mg, Then 0.75 mg, Then Placebo (Part A-Helathy)First 1.5 mg, Then 0.75 mg, Then Placebo (Part A-Healthy)First 0.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy)First 0.75 mg, Then Placebo, Then 0.5 mg (Part A-Healthy)First Placebo, Then 1.5 mg, Then 0.75 mg (Part A-Healthy)First 1.5 mg, Then 0.5 mg, Then Placebo (Part A-Healthy)First Placebo, Then 1.5 mg, Then 0.5 mg (Part A-Healthy)0.5 mg Dulaglutide (Part B-T2DM)0.75 mg Dulaglutide (Part B-T2DM)1.5 mg Dulaglutide (Part B-T2DM)Placebo (Part B-T2DM)
Started000000000000000011111010
Completed000000000000000010111010
Not completed00000000000000001000
Withdrew: Death00000000000000001000

Outcome measures

PrimaryPharmacokinetics: Maximum Concentration (Cmax) of Dulaglutide

Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.

Time frame:
Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics: Maximum Concentration (Cmax) of Dulaglutide
nanograms per milliliter (ng/mL)0.5 mg Dulaglutide (Part A-Healthy)0.75 mg Dulaglutide (Part A-Healthy)1.5 mg Dulaglutide (Part A-Healthy)0.5 mg Dulaglutide (Part B-T2DM)0.75 mg Dulaglutide (Part B-T2DM)1.5 mg Dulaglutide (Part B-T2DM)
Day 1 (Parts A and B)29.4 ± 3944.2 ± 1481.5 ± 2120.7 ± 1831.3 ± 2352.6 ± 28
Day 22 (Part B only)NA ± NANA ± NANA ± NA26.3 ± 2741.4 ± 1870.2 ± 19
PrimaryPharmacokinetics: Time of Maximum Observed Concentration (Tmax) of Dulaglutide

Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.

Time frame:
Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose
Reported as:
Median · hours
Pharmacokinetics: Time of Maximum Observed Concentration (Tmax) of Dulaglutide
hours0.5 mg Dulaglutide (Part A-Healthy)0.75 mg Dulaglutide (Part A-Healthy)1.5 mg Dulaglutide (Part A-Healthy)0.5 mg Dulaglutide (Part B-T2DM)0.75 mg Dulaglutide (Part B-T2DM)1.5 mg Dulaglutide (Part B-T2DM)
Day 1 (Parts A and B)48.02 (12.02 to 48.02)48.00 (24.00 to 48.00)48.00 (24.00 to 48.00)48.00 (47.92 to 72.00)48.00 (24.00 to 72.00)71.98 (24.00 to 96.00)
Day 22 (Part B only)NA (NA to NA)NA (NA to NA)NA (NA to NA)48.00 (12.00 to 48.02)47.98 (24.00 to 48.00)48.00 (23.97 to 96.00)
PrimaryPharmacokinetics: Area Under the Concentration-time Curve From Time Zero to 336 Hours Postdose (AUC[0-336]) of Dulaglutide

Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.

Time frame:
Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose
Reported as:
Geometric mean · nanograms*hours per milliliter (ng*h/mL)
Pharmacokinetics: Area Under the Concentration-time Curve From Time Zero to 336 Hours Postdose (AUC[0-336]) of Dulaglutide
nanograms*hours per milliliter (ng*h/mL)0.5 mg Dulaglutide (Part A-Healthy)0.75 mg Dulaglutide (Part A-Healthy)1.5 mg Dulaglutide (Part A-Healthy)0.5 mg Dulaglutide (Part B-T2DM)0.75 mg Dulaglutide (Part B-T2DM)1.5 mg Dulaglutide (Part B-T2DM)
Day 1 (Parts A and B; n = 6, 10, 11, 3, 8, 4)4500 ± 426410 ± 1411700 ± 123900 ± 75490 ± 1910300 ± 16
Day 22 (Part B only; n = 6, 10, 10NA ± NANA ± NANA ± NA4720 ± 77030 ± 1712500 ± 15
PrimaryPharmacokinetics: Half-life of Dulaglutide

Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.

Time frame:
Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose
Reported as:
Geometric mean · hours
Pharmacokinetics: Half-life of Dulaglutide
hours0.5 mg Dulaglutide (Part A-Healthy)0.75 mg Dulaglutide (Part A-Healthy)1.5 mg Dulaglutide (Part A-Healthy)0.5 mg Dulaglutide (Part B-T2DM)0.75 mg Dulaglutide (Part B-T2DM)1.5 mg Dulaglutide (Part B-T2DM)
Day 1 (Parts A and B; n=6, 10, 11, 3, 8, 4)85.1 (50.8 to 244)84.5 (60.2 to 228)82.9 (63.8 to 104)122 (106 to 133)113 (63.9 to 222)88.5 (69.6 to 111)
Day 22 (Part B only; n=NA, NA, NA, 6, 10, 9)NA (NA to NA)NA (NA to NA)NA (NA to NA)97.6 (71.9 to 122)106 (70.4 to 139)105 (80.0 to 134)
SecondaryPart B - Pharmacodynamics: Area Under the Plasma Glucose Time Curve From Time Zero to 4 Hours Postmeal (gAUC[0-4])

Pharmacodynamic parameters were assessed at baseline and on Days 3, 24, and 29 in Part B.

Time frame:
Baseline and Days 3, 24, and 29
Reported as:
Mean · millimoles*hours per liter (mmol*h/L)
Part B - Pharmacodynamics: Area Under the Plasma Glucose Time Curve From Time Zero to 4 Hours Postmeal (gAUC[0-4])
millimoles*hours per liter (mmol*h/L)0.5 mg Dulaglutide (Part B-T2DM)0.75 mg Dulaglutide (Part B-T2DM)1.5 mg Dulaglutide (Part B-T2DM)Placebo (Part B-T2DM
Baseline44.3 ± 10.658.1 ± 11.753.4 ± 8.1248.2 ± 7.00
Day 334.2 ± 6.1941.2 ± 11.932.2 ± 4.8746.1 ± 8.94
Day 2434.7 ± 7.1136.8 ± 7.0830.5 ± 4.5548.6 ± 9.10
Day 2937.6 ± 9.1138.1 ± 7.4031.8 ± 4.5746.9 ± 6.68

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Part A-Healthy)—0/16 (0%)1/16 (6.3%)
0.5 mg Dulaglutide (Part A-Healthy)—0/10 (0%)0/10 (0%)
0.75 mg Dulaglutide (Part A-Healthy)—0/11 (0%)2/11 (18.2%)
1.5 mg Dulaglutide (Part A-Healthy)—0/11 (0%)4/11 (36.4%)
Placebo (Part B-T2DM)—0/10 (0%)1/10 (10%)
0.5 mg Dulaglutide (Part B-T2DM)—1/11 (9.1%)5/11 (45.5%)
0.75 mg Dulaglutide (Part B-T2DM)—0/11 (0%)5/11 (45.5%)
1.5 mg Dulaglutide (Part B-T2DM)—0/10 (0%)2/10 (20%)
Most frequent serious events
Most frequent serious events
EventPlacebo (Part A-Healthy)0.5 mg Dulaglutide (Part A-Healthy)0.75 mg Dulaglutide (Part A-Healthy)1.5 mg Dulaglutide (Part A-Healthy)Placebo (Part B-T2DM)0.5 mg Dulaglutide (Part B-T2DM)0.75 mg Dulaglutide (Part B-T2DM)1.5 mg Dulaglutide (Part B-T2DM)
Myocardial infarctionCardiac disorders0/160/100/110/110/101/110/110/10
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPlacebo (Part A-Healthy)0.5 mg Dulaglutide (Part A-Healthy)0.75 mg Dulaglutide (Part A-Healthy)1.5 mg Dulaglutide (Part A-Healthy)Placebo (Part B-T2DM)0.5 mg Dulaglutide (Part B-T2DM)0.75 mg Dulaglutide (Part B-T2DM)1.5 mg Dulaglutide (Part B-T2DM)
Decreased appetiteMetabolism and nutrition disorders0/160/100/112/110/102/112/111/10
Abdominal discomfortGastrointestinal disorders1/160/101/111/110/101/111/111/10
NauseaGastrointestinal disorders0/160/101/111/110/100/110/111/10
VomitingGastrointestinal disorders0/160/101/110/110/100/110/111/10
Blood glucose increasedInvestigations0/160/100/110/111/100/110/110/10
LeukopeniaBlood and lymphatic system disorders0/160/100/110/110/101/110/110/10
Atrial tachycardiaCardiac disorders0/160/100/110/110/101/110/110/10
TachycardiaCardiac disorders0/160/100/110/110/101/110/110/10
Abdominal distensionGastrointestinal disorders0/160/100/110/110/100/111/110/10
Abdominal painGastrointestinal disorders0/160/100/110/110/101/110/110/10

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Part A-Healthy0.5 mg Dulaglutide (Part B-T2DM)0.75 mg Dulaglutide (Part B-T2DM)1.5 mg Dulaglutide (Part B-T2DM)Placebo (Part B-T2DM)Total
Mean29.2 ± 5.658.2 ± 4.256.9 ± 13.155.8 ± 8.551.8 ± 8.348.4 ± 14.5
Sex: Female, Male
Sex: Female, Male(Participants)Part A-Healthy0.5 mg Dulaglutide (Part B-T2DM)0.75 mg Dulaglutide (Part B-T2DM)1.5 mg Dulaglutide (Part B-T2DM)Placebo (Part B-T2DM)Total
Female0333312
Male16887746
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A-Healthy0.5 mg Dulaglutide (Part B-T2DM)0.75 mg Dulaglutide (Part B-T2DM)1.5 mg Dulaglutide (Part B-T2DM)Placebo (Part B-T2DM)Total
Hispanic or Latino000000
Not Hispanic or Latino161111101058
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A-Healthy0.5 mg Dulaglutide (Part B-T2DM)0.75 mg Dulaglutide (Part B-T2DM)1.5 mg Dulaglutide (Part B-T2DM)Placebo (Part B-T2DM)Total
American Indian or Alaska Native000000
Asian161111101058
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White000000
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)Part A-Healthy0.5 mg Dulaglutide (Part B-T2DM)0.75 mg Dulaglutide (Part B-T2DM)1.5 mg Dulaglutide (Part B-T2DM)Placebo (Part B-T2DM)Total
China161111101058
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beijing, 100034, China
09

References and documents

Publications

  • Xu J, Zhang Y, Li Y, Zhao X, Zhou W, Loghin C, Tham LS, Cui X, Cui Y, Wang W. Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study. Adv Ther. 2022 Jan;39(1):488-503. doi: 10.1007/s12325-021-01921-5. Epub 2021 Nov 17. PubMed 34787823 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2012
First posted
Aug 17, 2012
Start
Aug 2012
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Results first posted
Mar 7, 2016
Last update
Mar 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01667900
Responsible party
Sponsor
First posted
Aug 17, 2012
Start date
Aug 2012
Primary completion
Jun 2014
Completion
Jun 2014
Results posted
Mar 7, 2016
Last update
Mar 7, 2016

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM- 5 PM Eastern time (UTC/GMT -5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion